NYSE - Nasdaq Real Time Price
USD
Smith & Nephew plc (SNN)
30.28
+0.24
(+0.80%)
At close: June 29 at 4:00:02 PM EDT
Trade SNN on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for SNN
- Previous Close
30.04 - Open
30.41 - Bid --
- Ask --
- Day's Range
30.20 - 30.47 - 52 Week Range
29.08 - 38.79 - Volume
1,004,946 - Avg. Volume
1,176,484 - Market Cap (intraday)
12.794B - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
21.17 - EPS (TTM)
1.43 - Earnings Date --
- Forward Dividend & Yield 0.78 (2.58%)
- Ex-Dividend Date Mar 27, 2026
- 1y Target Est
34.99
Recent News
View More
![[Latest] Global Orthopedic Soft Tissue Repair Market Size/Share Worth USD 15.38 Billion by 2035 at a 9.6 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)](https://s.yimg.com/uu/api/res/1.2/JDc8Q43tjkZAOscxTVa7kA--~B/Zmk9c3RyaW07aD02Mzt3PTg0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp)
Performance Overview
Trailing total returns as of 6/30/2026, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
SNN
7.08%
FTSE 100 (^FTSE)
6.16%
1-Year Return
SNN
2.56%
FTSE 100 (^FTSE)
20.35%
3-Year Return
SNN
4.35%
FTSE 100 (^FTSE)
39.99%
5-Year Return
SNN
20.02%
FTSE 100 (^FTSE)
49.82%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/29/2026
-
Market Cap
12.76B
-
Enterprise Value
15.53B
-
Trailing P/E
21.15
-
Forward P/E
13.66
-
PEG Ratio (5yr expected)
1.21
-
Price/Sales (ttm)
2.14
-
Price/Book (mrq)
2.42
-
Enterprise Value/Revenue
2.52
-
Enterprise Value/EBITDA
10.13
Financial Highlights
Profitability and Income Statement
-
Profit Margin
10.14%
-
Return on Assets (ttm)
5.27%
-
Return on Equity (ttm)
11.84%
-
Revenue (ttm)
6.16B
-
Net Income Avi to Common (ttm)
625M
-
Diluted EPS (ttm)
1.43
Balance Sheet and Cash Flow
-
Total Cash (mrq)
557M
-
Total Debt/Equity (mrq)
62.90%
-
Levered Free Cash Flow (ttm)
876.63M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
Smith & Nephew Earnings: Sports Medicine Strength Offsets Knee Softness
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
RatingPrice Target -
Smith & Nephew Earnings: Attention to Operational Detail Paid Off in 2025
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
RatingPrice Target -
Smith & Nephew Earnings: Attention to Operational Detail Paid Off in 2025
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
RatingPrice Target -
Smith & Nephew Earnings: Attention to Operational Detail Paid Off in 2025
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
RatingPrice Target
